Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
Chipotle Mexican Grill (CMG) : Cramer spoke with Jack Hartung, chief financial officer of Chipotle Mexican Grill, the restaurant chain with shares lower by 24% for the year while the company struggles to recover from last year's health issues.
Hartung said that the restaurant industry overall has seen softness due to the negativity and uncertainty surrounding the election and he hopes to see things improve soon at Chipotle's 2,178 locations across the country.
When asked about their recovery, Hartung said sales are increasing by about 1% per month and he's confident it's only a matter of when, not if, they return to their previous sales levels. He said that currently the focus is on the recovery and delivering a great experience. Once that is complete, they will turn toward increasing efficiencies and margins.
Asked whether activist shareholders are a distraction, Hartung said he found the opposite to be true: All of their shareholders, he said, are aligned with promoting long-term value.
Cramer said while Chipotle has begun to bottom, history has told us that food safety scares take 18 months to fully recover and Chipotle is not ready to deliver just yet.
Following last night's stunning election results, we're dealing with a different stock market, Cramer told viewers. And that means re-rating a host of sectors. The most obvious changes will be in the health-care sector, where the Republicans aren't likely to follow Hillary Clinton's planned path of Congressional inquiries and executive actions to keep prices in check.
After being beaten down for months, the health-care stocks are now dirt cheap, Cramer said, but that doesn't mean that every stock is a winner.
CVS Health (CVS) plummeted 12% Tuesday after the company reported, and Cramer said that Valeant Pharmaceuticals (VRX) remains "toxic." Investors should also avoid stocks like AmerisourceBergen (ABC) , which is in the middle of a vicious price war.
That leaves Merck, with its 2.7% yield, as one of the best bets in the sector, Cramer said, noting the company leads in next-generation cancer therapies. He was also a fan of Pfizer with its 3.7% yield.
Turning to biotech, Cramer continued to recommend Celgene, which is growing sales at 27%. He said "something good is happening" at the company. He was also bullish on Allergan -- the fastest growing company, with the lowest multiple in the industry.
Finally, Cramer recommended Walgreens Boots Alliance (WBA) , which posted excellent earnings this quarter.
Johnson said that while it never hurts to have some rules and regulations go away, having Donald Trump in the White House isn't likely to affect his company that much because they don't drill on a lot of federal land. What is more important however, is getting more pipelines built to get the oil flowing and reduce rail traffic for oil, he said.
When asked for his outlook on the oil market, Johnson predicted supply and demand equilibrium by the end of 2017, which is why Carrizo is scaling up ahead of that by adding an additional drilling rigs for 2017.
Cramer said Johnson is a man who knows how to run an oil company.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.